RT Journal Article
SR Electronic
T1 A multiplex protein panel assay determines disease severity and is prognostic about outcome in COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.03.21267253
DO 10.1101/2021.12.03.21267253
A1 Wang, Ziyue
A1 Cryar, Adam
A1 Lemke, Oliver
A1 Ludwig, Daniela
A1 Tober-Lau, Pinkus
A1 Helbig, Elisa Theresa
A1 Blake, Daniel
A1 Lane, Catherine S
A1 Sayers, Rebekah L
A1 Mueller, Christoph
A1 Zeiser, Johannes
A1 Townsend, StJohn
A1 Demichev, Vadim
A1 Mülleder, Michael
A1 Kurth, Florian
A1 Sirka, Ernestas
A1 Hartl, Johannes
A1 Ralser, Markus
YR 2021
UL http://medrxiv.org/content/early/2021/12/05/2021.12.03.21267253.abstract
AB Global healthcare systems continue to be challenged by the COVID-19 pandemic, and there is a need for clinical assays that can both help to optimize resource allocation and accelerate the development and evaluation of new therapies. Here, we present a multiplex proteomic panel assay for the assessment of disease severity and outcome prediction in COVID-19. The assay quantifies 50 peptides derived from 30 COVID-19 severity markers in a single measurement using analytical flow rate liquid chromatography and multiple reaction monitoring (LC-MRM), on equipment that is broadly available in routine and regulated analytical laboratories. We demonstrate accurate classification of COVID-19 severity in patients from two cohorts. Furthermore, the assay outperforms established risk assessments such as SOFA and APACHE II in predicting survival in a longitudinal COVID-19 cohort. The prognostic value implies its use for support of clinical decisions in settings with overstrained healthcare resources e.g. to optimally allocate resources to severely ill individuals with high chance of survival. It can furthermore be helpful for monitoring of novel therapies in clinical trials.Competing Interest StatementEM Scientific Limited (t/a Inoviv) and Charite Universitaetsmedizin Berlin filed joint patent applications for the protein panel assay described herein - United States Application No: 63/156291 and 63/283787. Ernestas Sirka and Adam Cryar are/were employees of EM Scientific Limited (t/a Inoviv) Daniel Blake, Rebekah L Sayers and Catherine S Lane are employees of SCIEX. Christoph Mueller and Johannes Zeiser are employees of Agilent Technologies.Funding StatementThis research was funded in part by the European Research Council (ERC) under grant agreement ERC SyG 2020 951475 (to M.R), the Wellcome Trust (IA 200829/Z/16/Z to M.R.). The work was further supported by the Ministry of Education and Research (BMBF), as part of the National Research Node Mass spectrometry in Systems Medicine (MSCoresys), under grant agreements 031L0220 and 161L0221. J.H. was supported by a Swiss National Science Foundation (SNF) Postdoc Mobility fellowship (project number 191052). This study was further supported by the German Federal Ministry of Education and Research (NaFoUniMedCOVID-19 NUM-NAPKON, FKZ: 01KX2021). The study was co-funded by the UKs innovation agency, Innovate UK, under project numbers 75594 and 56328.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Pa-COVID-19 study was approved by the ethics committee of Charite - Universitaetsmedizin Berlin (EA2/066/20) and conducted in accordance with the Declaration of Helsinki and guidelines of Good Clinical Practice (ICH 1996).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.